PMC:6707402 / 10836-11384 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/6707402","sourcedb":"PMC","sourceid":"6707402","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6707402","text":"The most commonly reported gastrointestinal adverse reactions were nausea and vomiting. The incidence of nausea seems to be less common with the transdermal administration of DMSO compared with intravenous administration. The majority of studies reported an incidence of nausea between 2–14%, with the exception of one study, reporting an incidence of 32% 2. In one study that failed to specify the dose, 8 of 42 patients reported nausea and anorexia, but the symptoms disappeared in five of the eight patients when the dose of DMSO was reduced 45.","tracks":[{"project":"MyTest","denotations":[{"id":"31489176-1055563-30448078","span":{"begin":356,"end":357},"obj":"1055563"},{"id":"31489176-5232269-30448079","span":{"begin":545,"end":547},"obj":"5232269"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"attributes":[{"subj":"31489176-1055563-30448078","pred":"source","obj":"MyTest"},{"subj":"31489176-5232269-30448079","pred":"source","obj":"MyTest"}]},{"project":"2_test","denotations":[{"id":"31489176-1055563-30448078","span":{"begin":356,"end":357},"obj":"1055563"},{"id":"31489176-5232269-30448079","span":{"begin":545,"end":547},"obj":"5232269"}],"attributes":[{"subj":"31489176-1055563-30448078","pred":"source","obj":"2_test"},{"subj":"31489176-5232269-30448079","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"MyTest","color":"#d9ec93","default":true},{"id":"2_test","color":"#e593ec"}]}]}}